

September 30, 2019

Via EDGAR

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549-3720

Attention: Sonia Bednarowski  
Dietrich King  
Keira Nakada  
Kevin Vaughn

Re: Acceleration Request for Aprea Therapeutics, Inc.  
Registration Statement on Form S-1 (File No. 333-233662)

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Aprea Therapeutics, Inc. (the "**Company**"), hereby requests that the effective date of the Company's Registration Statement on Form S-1, Registration Number 333-233662 (the "**Registration Statement**") be accelerated so that the Company's Registration Statement will become effective at 4:00 P.M., Eastern Time or as soon thereafter as practicable, on October 2, 2019, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission.

*[Signature Page Immediately Follows]*

---

We would appreciate it if, as soon as the Registration Statement is declared effective, you would so inform Istvan A. Hajdu of Sidley Austin LLP at (212) 839-5651.

Very truly yours,

/s/ Christian S. Schade

Christian S. Schade  
Chief Executive Officer

cc: Scott M. Coiante, Aprea Therapeutics, Inc.  
Geoffrey W. Levin, Sidley Austin LLP  
Samir A. Gandhi, Sidley Austin LLP  
Istvan A. Hajdu, Sidley Austin LLP  
Richard D. Truesdell, Jr., Davis Polk & Wardwell LLP  
Derek Dostal, Davis Polk & Wardwell LLP

---